Skip to content

Ozempic nausea, Zepbound nausea and the other GLP-1 labels

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Ozempic nausea is the most frequently reported reaction in that label's table: 15.8% to 20.3% of adults, against 6.1% on placebo. All eight GLP-1 labels list nausea. In adult trials it was reported by 44% of patients on Wegovy 2.4 mg (16% on placebo) and 25% to 29% on Zepbound (8% on placebo). Several labels tie it to dose increases. If it keeps you from eating or drinking normally, tell your prescriber.

Key takeaways

  • All eight GLP-1 labels list nausea, and several tie it to the weeks when the dose is being raised.
  • No label says how long an episode of nausea lasts.
  • Tell your prescriber if nausea keeps you from eating or drinking normally, or doesn't ease after a dose increase.
  • Nausea with vomiting or diarrhea can leave you dehydrated, and the labels link dehydration to kidney injury.
  • Severe or persistent abdominal pain needs prompt medical attention.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Nausea8%25%29%28%

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
ReactionPlacebon=2355 mgn=23710 mgn=24015 mgn=241
Nausea4%12%15%18%

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Nausea16%44%
Wegovy: Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction · Adults with obesity (BMI of 30 or more) in two 72-week, double-blind, randomized, placebo-controlled, 3-armed trials (Study 8 and Study 9, the second in patients with type 2 diabetes). Dysesthesia, abdominal pain, fatigue and dizziness are grouped terms.
ReactionPlacebon=303Wegovy injection 2.4 mg once weeklyn=304Wegovy injection 7.2 mg once weeklyn=1311
Nausea13%35%39%
Wegovy: Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction · Pediatric patients aged 12 years and older with obesity in a 68-week, double-blind, randomized, placebo-controlled trial of Wegovy 2.4 mg injection.
ReactionPlacebon=67Wegovy injection 2.4 mg once weeklyn=133
Nausea18%42%

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Ozempic: Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionPlacebon=262Ozempic 0.5 mgn=260Ozempic 1 mgn=261
Nausea6.1%15.8%20.3%

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Nausea10%26%34%35%

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Rybelsus: Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials of semaglutide tablets (Rybelsus); mean duration of exposure was 41.8 weeks. The table excludes hypoglycemia.
ReactionPlacebon=362Semaglutide tablets 7 mgn=356Semaglutide tablets 14 mgn=356
Nausea6%11%20%

FDA label: Rybelsus, Revised: 1/2026 (DailyMed version 14)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Nausea13.8%39.3%
Saxenda: Table 3. Adverse Reactions Occurring in ≥3% of SAXENDA-treated Pediatric Patients and More Frequently than Placebo in a 56 Week Clinical Trial · Pediatric patients aged 12 years and older with obesity, without type 2 diabetes, in a 56-week placebo-controlled trial. The hypoglycemia row is defined as blood glucose below 70 mg/dL with symptoms.
ReactionPlacebon=126Saxendan=125
Nausea14.3%42.4%

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
ReactionPlacebon=5680.75 mgn=8361.5 mgn=834
Nausea5.3%12.4%21.1%
Trulicity: Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks · Clinical trial of 1842 adults with type 2 diabetes treated with Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly as add-on to metformin, through 36 weeks (no placebo arm).
Reaction1.5 mgn=6123 mgn=6164.5 mgn=614
Nausea13.4%15.6%16.4%

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

Feeling sick to your stomach on a GLP-1? Tell your prescriber if nausea keeps you from eating or drinking normally, if it comes with vomiting or diarrhea that could leave you dehydrated, or if it doesn’t ease after a dose increase. Severe or persistent abdominal pain needs prompt medical attention.

Nausea is the one reaction all eight labels put in their tables, and in most of them it’s the top row. The tables below show every label’s figures, and this page explains how to read them.

How often do the labels report nausea?

Each figure is the share of trial patients who reported nausea at least once. Next to it is the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.

Weight management trials in adults

  • Wegovy 2.4 mg injection (three trials, up to 68 weeks): 44%, with 16% on placebo. In the separate trials of the 7.2 mg dose in adults with obesity, 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo.
  • Zepbound (two pooled trials, up to 72 weeks): 25% at 5 mg, 29% at 10 mg and 28% at 15 mg, with 8% on placebo.
  • Foundayo (two pooled trials, up to 72 weeks): 26% at 5.5 mg, 34% at 9 mg and 35% at 17.2 mg, with 10% on placebo.
  • Saxenda (five trials): 39.3%, with 13.8% on placebo.

Type 2 diabetes trials in adults

  • Ozempic injection (two trials): 15.8% at 0.5 mg and 20.3% at 1 mg, with 6.1% on placebo.
  • Mounjaro (two pooled trials): 12% at 5 mg, 15% at 10 mg and 18% at 15 mg, with 4% on placebo.
  • Rybelsus (two trials; the label also covers Ozempic tablets): 11% at 7 mg and 20% at 14 mg, with 6% on placebo.
  • Trulicity (pooled trials): 12.4% at 0.75 mg and 21.1% at 1.5 mg, with 5.3% on placebo. In a later trial with no placebo arm: 13.4% at 1.5 mg, 15.6% at 3 mg and 16.4% at 4.5 mg.

Adolescents aged 12 and older with obesity

  • Wegovy 2.4 mg: 42%, with 18% on placebo.
  • Saxenda: 42.4%, with 14.3% on placebo.

These are separate trials in different groups of people, so you can’t line the numbers up to say which medicine causes less nausea. Look at the placebo rows too. Between 4% and 18% of people who got no active drug also reported nausea.

When does nausea happen?

Mostly while the dose is being raised, which the labels call dose escalation. Here’s what the labels that address timing say:

  • Zepbound: the majority of nausea, vomiting and diarrhea events “occurred during dose escalation and decreased over time.”
  • Foundayo: the incidence “was higher during the FOUNDAYO dosage escalation period and decreased over time.”
  • Ozempic and Rybelsus: the majority of reports occurred during dose escalation.
  • Wegovy: gastrointestinal reactions “were most frequently reported during dosage escalation.”
  • Saxenda: “The percentage of patients reporting nausea declined as treatment continued.”

No label says how long an episode lasts.

Every one of these medicines starts at a low dose and steps up for this reason. The titration schedule tool shows when each step falls for your medicine. Whether to stay longer on a dose because of nausea is your prescriber’s decision. The label doesn’t leave that to you.

Which warnings relate to nausea?

Two, and they’re the reason to report nausea, not put up with it in silence.

Dehydration and kidney injury. Every label carries a warning about acute kidney injury due to volume depletion, meaning losing too much fluid. Zepbound’s describes postmarketing reports (reports made after approval) of acute kidney injury, “in some cases requiring hemodialysis,” a treatment in which a machine filters the blood. It says the majority occurred in patients whose nausea, vomiting or diarrhea led to dehydration. The Wegovy and Rybelsus labels tell prescribers to monitor kidney function in patients who report reactions that could lead to volume depletion, especially while the dose is being started and raised.

Pancreatitis. The Wegovy, Ozempic and Saxenda labels describe the signs of acute pancreatitis, an inflammation of the pancreas, as persistent or severe abdominal pain, sometimes radiating to the back, “which may or may not be accompanied by nausea or vomiting.” Nausea alone is common. Nausea alongside that kind of pain is different. See abdominal pain.

The labels also warn that stomach and bowel reactions are sometimes severe, and they say the medicines are not recommended in people with severe gastroparesis (a stomach that empties very slowly).

When to contact your prescriber

The label text is written for clinicians, and it asks them to act on what patients report. So speak up. Tell your prescriber if nausea is keeping you from eating or drinking normally, if it comes with vomiting or diarrhea that could leave you dehydrated, or if it doesn’t ease after a dose increase. Severe or persistent abdominal pain needs prompt medical attention.

Your pharmacist can tell you what’s appropriate for nausea with your other medicines. For the wider picture, see the side effects guide.

Frequently asked questions

Does Ozempic cause nausea?

Yes, it's the most frequently reported reaction in the Ozempic injection label's table. In two placebo-controlled trials in adults with type 2 diabetes, 15.8% of patients on 0.5 mg and 20.3% on 1 mg reported it, compared with 6.1% on placebo. The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised.

How long does nausea last on Wegovy or Zepbound?

Neither label gives a number of days or weeks. Wegovy's says stomach and bowel reactions were most frequently reported during dosage escalation, while the dose was being raised. Zepbound's says most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. That describes the whole trial group, not what you personally should expect. If your nausea won't go away, raise it with your prescriber.

Is nausea worse at higher doses?

It depends on the label. Mounjaro's table shows 12% at 5 mg, 15% at 10 mg and 18% at 15 mg. Zepbound's shows 25%, 29% and 28% for the same three doses, so the top dose wasn't the highest. Rybelsus shows 11% at 7 mg and 20% at 14 mg. The labels tie nausea more firmly to the weeks of raising the dose than to any one dose.

Do people stop their GLP-1 because of nausea?

Some do. In the adult Wegovy 2.4 mg trials, nausea led 1.8% of patients to stop for good, against 0.2% on placebo, and it was the most common reaction behind stopping. In the adult Saxenda trials the figures were 2.9% and 0.2%. If nausea has you thinking about stopping, talk to your prescriber first.

Does Zepbound cause nausea?

Yes, nausea is in the Zepbound label's table. In two pooled weight reduction trials of up to 72 weeks, 25% of patients on 5 mg, 29% on 10 mg and 28% on 15 mg reported it, compared with 8% on placebo. The label says most nausea, vomiting and diarrhea events occurred during dose escalation (while the dose was being raised) and decreased over time.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.